| 徐浩,史大卓,陈可冀,马晓昌,毛节明,吕树铮,陈明哲.芎芍胶囊预防冠状动脉介入治疗后再狭窄的临床研究[J].,2000,(7):494-497 |
| 芎芍胶囊预防冠状动脉介入治疗后再狭窄的临床研究 |
| Clinical Effect of Xiongshao Capsule on Preventing Restenosis Post-PTCA or/and Stenting |
| |
| DOI： |
| 中文关键词: 芍芍胶囊 血管成形术 支架 再狭窄 |
| 英文关键词:Xiongshao capsule angiography stenting restenosis |
| 基金项目:国家“九五”攻关课题部分内容!（No．96－906－06－01） |
| Author Name | Affiliation | | 徐浩 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 | | 史大卓 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 | | 陈可冀 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 | | 马晓昌 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 | | 毛节明 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 | | 吕树铮 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 | | 陈明哲 | XU Hao, SHI Dazhuo, CHEN Keji, et al (Xiyuan Hospital, China Academy of Traditional Chinese Medicine, Beijing (100091 |
|
| Hits: 2691 |
| Download times: 1791 |
| 中文摘要: |
| 目的：观察芎芍胶囊预防冠状动脉介入治疗后再狭窄的临床疗效。方法：６５例经皮冠状动脉腔内成形术（ＰＴＣＡ）或（及）支架植入术成功的冠心病患者，随机分为西药常规治疗（对照）组３７例和西药常规加芍芍胶囊治疗（加中药）组２８例。对患者术后６个月的心绞痛复发、血瘀证积分值变化、冠脉造影等进行随访观察。结果：加中药组心绞痛复发率显著低于对照组（Ｐ＜０．０５）。两组患者共有２６例复查冠脉造影，其中加中药组１０例中，再狭窄４例；对照组１６例中，再狭窄１３例，两组比较再狭窄发生率有显著性差异（Ｐ＜０．０５）。治疗后血瘀证积分值（分）加中药组（１６．８９±５．４５）与对照组（２１．４１±４．９８）比较有显著性差异（ Ｐ＜ ０． ０１）。Ｌｏｇｉｓｔｉｃ回归分析发现，加用中药及术前血瘀证积分值是再狭窄发生与否的重要影响因素（Ｐ＜０．０５）。血瘀证积分值＞２５较血瘀证积分值≤２５的患者再狭窄发生的比数比为６．５。结论：芎芍胶囊可明显降低冠状动脉介入治疗后的冠脉造影随访再狭窄的发生，减少心绞痛复发并改善患者的血瘀状态；血瘀证的轻重程度是冠状动脉介入治疗后再狭窄发生与否的重要影响因素，其积分值＞２５可考虑作为冠状动脉介入治疗后再狭窄发生的 |
| 英文摘要: |
| To evaluate the effect of Xiongshao capsule (XSC) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Methods: Sixty-five coronary heart disease (CHD) patients with successful angioplasty or and stenting were randomly divided into the control group (37 cases, routine treatment) and the XSC group (28 cases, routine treatment plus XSC). The recurrent of angina, changing of blood stasis syndrome score (BSSS) and coronary angiography within 6 months after coronary angioplasty or/ and stenting were observed. Results: Recurrent angina occurred in 6 out of 28 patients in the XSC group, which was much better than that in the control group, 18 out of 37 patients (P< 0. 05). Follow-up angiography was performed in 26 including 10 patients in the XSC group (restenosis was observed in 4 cases), and 16 cases in the control group (restenosis in 13 cases), there was significant difference between the XSC group and the control group (P< 0. 05). For BSSS at follow-up, XSC group was much lower than that of the control group (P < 0. 01). Logistic regress analysis showed the combination with XSC and the base-line BSSS were important affecting factors on the occurrence of restenosis (P < 0. 05 ). The odds ratio of the occurrence of angiographic restenosis (BSSS > 25 to BSSS≤25 ) was 6. 5. Conclusions: XSC could markedly reduce the occurrence of restenosis recurrence of angina and improve the condition of blood stasis after coronary angioplasty or/and stenting. The seventy of blood stasis syndrome was an important affecting factor on the occurrence of restenosis. BSSS >25 can be served as one of the predicting factors of the occurrence of restenosis after coronary angioplasty or/and stenting. |
| View Full Text View/Add Comment Download reader |
|
|
|
